Clinical, histological and molecular reversibility of zidovudine myopathy

Ferran Masanés, Antoni Barrientos, Mireia Cebrián, Enric Pedrol, Oscar Miró, Jordi Casademont, Josep M. Grau

Research output: Contribution to journalArticle

27 Scopus citations

Abstract

The use of zidovudine in the treatment of human immunodeficiency virus infection has been associated with toxic mitochondrial myopathy. There are some reported cases of improvement after stopping the drug, but in only one were molecular studies performed. We therefore studied three patients with toxic AZT myopathy during AZT treatment and after drug withdrawal. Clinical complaints disappeared within the next three months after drug cessation. In all cases, histological data of mitochondrial abnormalities also disappeared. Molecular studies showed an initial depletion of the total amount of mitochondrial DNA with respect to healthy controls which was reversible after AZT withdrawal. This work demonstrates that AZT myopathy is reversible not only at a clinical and histological, but also at a molecular level.

Original languageEnglish (US)
Pages (from-to)226-228
Number of pages3
JournalJournal of the Neurological Sciences
Volume159
Issue number2
DOIs
StatePublished - Aug 14 1998
Externally publishedYes

Keywords

  • Mitochondrial toxicity
  • Molecular studies
  • Toxic myopathy
  • Zidovudine

ASJC Scopus subject areas

  • Aging
  • Clinical Neurology
  • Surgery
  • Developmental Neuroscience
  • Neurology
  • Neuroscience(all)

Fingerprint Dive into the research topics of 'Clinical, histological and molecular reversibility of zidovudine myopathy'. Together they form a unique fingerprint.

  • Cite this